BriaCell Therapeutics: Jumps as lead drug helps control disease across trials

Briacell Therapeutics

12/04/2021 13:23

** Shares of drug developer BriaCell Therapeutics Corp
 BCTX.O  jump 14% to $5.92 premarket
    ** Co presents data from studies of its lead drug candidate
Bria-IMT at American Association for Cancer Research (AACR)
Annual Meeting 2021 
    ** Data shows therapy helped in disease control in advanced
breast cancer patients, co says  urn:newsml:reuters.com:*:nGNXWmX1x
    ** Patients with low or undetectable levels of circulating
cancer cells were more likely to benefit from therapy - BCTX
    ** Patients were treated with either Bria-IMT alone or in
combination with Merck & Co's  MRK.N  Keytruda and Incyte Corp's
 INCY.O  retifanlimab
    ** Stock down 48.3% in last 12 months

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3635;))